Learned helplessness linked to arthritis disease outcomes

Learned helplessness linked to arthritis disease outcomes
For patients with inflammatory polyarthritis, learned helplessness correlates with disease outcomes and seems to mediate the association between socioeconomic status and disease outcomes, according to a study published in the August issue of Arthritis Care & Research.

(HealthDay) -- For patients with inflammatory polyarthritis (IP), learned helplessness (LH) correlates with disease outcomes and seems to mediate the association between socioeconomic status (SES) and disease outcomes, according to a study published in the August issue of Arthritis Care & Research.

Elizabeth M. Camacho, from the University of Manchester in the United Kingdom, and associates investigated the cross-sectional relationship between SES and LH and disease outcomes in 553 patients with recent-onset IP, recruited to the Norfolk Register. SES was assessed using the Index of Multiple Deprivation 2007; LH was evaluated using the Rheumatology Attitudes Index; and disease outcome was assessed using the Health Assessment Questionnaire (HAQ) and Disease Activity Score.

The researchers found that patients with the lowest SES had significantly worse outcomes (median difference in HAQ score, 0.42) compared with those with the highest SES. Patients with low LH had a significantly better outcome, and those with high LH had a significantly worse outcome, compared to patients with normal LH. LH likely mediated the correlation between SES and disease outcome (P = 0.04).

"LH is robustly associated with cross-sectional disease outcome in patients with IP, and appears to mediate the relationship between SES and disease outcome," the authors write. "As LH is potentially modifiable, these findings have potential clinical implications."

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

What Causes Irritability In Menopause?

date Jun 09, 2009

Irritability is frequently the main presenting complaint of perimenopausal and postmenopausal women; yet, studies specifically researching on irritability in this population are lacking.

Recommended for you

Patients grapple with high cost of arthritis medications

date Apr 21, 2015

The first national investigation of Medicare coverage of biologic disease modifying drugs (DMARDs) found that in starting a single biologic DMARD, patients face more than $2,700 in copayments each year before receiving relief ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.